RSS

PhoreMost

PhoreMost, UK-based biopharmaceutical company, has entered into a collaboration with o2h discovery (o2h) — an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage. more

News

UK-based biopharmaceutical company, PhoreMost, has completed a Series A investment round worth £11 million, which will be used to expand operations on the Babraham Research Campus and progress several novel drug targets. more

News

Cancer immune-oncology company, NeoPhore, and developer of a next-generation phenotypic screening platform, PhoreMost, have been granted funding from Innovate UK in support of the development of novel small-molecule cancer immunotherapy programme. more

News

PhoreMost, UK-based biopharmaceutical company, has signed a collaborative agreement with Plexxikon, the small molecule structure-guided R&D centre of Daiichi Sankyo, for the identification of novel drug targets. more

News

UK based fund manager, Sixth Element Capital, has announced a £3 million investment in a spin out company from PhoreMost — NeoPhore. more

News

Biopharmaceutical company PhoreMost has entered into a research collaboration with the laboratory of Professor David Rubinsztein at the University of Cambridge. more

News

PhoreMost has been selected to receive a funding award of £1.4M from Innovate UK to develop its lead oncology programme targeting mutant KRAS cancers. more

News